Inventor
GAUDET FRANCOIS
FR12 patents
⚠️ This page may combine multiple inventors who share the name “GAUDET FRANCOIS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JANSSEN BIOTECH INC
7 patentsUS12077592B2Sep 3, 2024
GPRC5D chimeric antigen receptors and cells expressing the same
JANSSEN BIOTECH INC3 citations69
US11884722B2Jan 30, 2024
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
JANSSEN BIOTECH INC1 citations69
US11603405B2Mar 14, 2023
Anti-CD3 antibodies and uses thereof
JANSSEN BIOTECH INC4 citations69
US10844122B2Nov 24, 2020
Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
JANSSEN BIOTECH INC4 citations68
US11466082B2Oct 11, 2022
Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof
JANSSEN BIOTECH INC2 citations67
US12065500B2Aug 20, 2024
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JANSSEN BIOTECH INC0 citations52
US12012461B2Jun 18, 2024
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JANSSEN BIOTECH INC0 citations52
JANSSEN PHARMACEUTICA NV
4 patentsUS10562968B2Feb 18, 2020
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
JANSSEN PHARMACEUTICA NV18 citations90
US9850310B2Dec 26, 2017
CD123 binding agents and uses thereof
JANSSEN PHARMACEUTICA NV23 citations90
US10072088B2Sep 11, 2018
Anti-BCMA antibodies and uses thereof
JANSSEN PHARMACEUTICA NV30 citations89
US11685777B2Jun 27, 2023
Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
JANSSEN PHARMACEUTICA NV1 citations69